Format

Send to

Choose Destination
Blood. 2019 May 30;133(22):2452-2455. doi: 10.1182/blood.2019896688. Epub 2019 Mar 27.

Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.

Author information

1
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
2
Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY; and.
3
Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
PMID:
30917955
PMCID:
PMC6543520
[Available on 2020-05-30]
DOI:
10.1182/blood.2019896688

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center